GlobeNewswire Inc.··Oculis Holding AgOculis to Present Pivotal Optic Neuritis Data as Privosegtor Advances Toward FDA Review
Oculis presents Phase 2 data for Privosegtor, an FDA Breakthrough-designated optic neuritis therapy showing improved visual acuity and reduced nerve damage, advancing toward Phase 3 registration trial.
OCSOCSAWFDA Breakthrough Therapy DesignationPrivosegtor